CBRS18089 / S1418 / Alissa Huston
Basic Study Information
Purpose:Location: University of Rochester
This randomized phase III trial studies how well pembrolizumab works in treating patients
with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Lauren Mitchell
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search